Table 1 Baseline characteristics of non-SVR and SVR patients receiving DCV/ASV therapy.

Variable		Non-SVR (n = 32)	SVR (control) (n = 72)	p
Age (years)	Median (Range)	67.5 (43–81)	69.5 (42–82)	0.896^a
Sex	Male/Female	12/20	27/45	0.386^b
Liver cirrhosis	Yes/No	15/17	24/48	0.197^a
HCV-RNA (logIU/mL)	Median (Range)	6.35 (3.6–7.3)	6.40 (5.2–7.9)	0.523^b
Pretreatment ALT level (U/L)	Median (Range)	38 (13–123)	43 (6–183)	0.717^a
Pretreatment T-BIL level (mg/dL)	Median (Range)	0.7 (0.4–2.9)	0.8 (0.4–8.2)	0.119^a
Pretreatment Platelet (*10⁴/L)	Median (Range)	14.1 (4.1–44.6)	12.7 (4.4–34.1)	0.612^a
Previous anti-HCV therapy
IFN monotherapy	Yes/No	5/27	3/69	0.103^b
PEG-IFN plus RIB	Yes/No	22/10	46/26	0.663^b
TRV plus PEG-IFN RIB	Yes/No	1/31	5/67	0.664^b
SMV plus PEG-IFN RIB	Yes/No	8/24	0/72	<0.0001^b
Pretreatment RAVs (Sanger sequencing)
NS5A-Y93H	+/−	1/16	18/54	0.022^b
NS5A-L31M/V/I	+/−	5 /27	1/71	0.010^b

ALT, alanine aminotransferase; T-BIL, total-bilirubin; IFN, interferon; PEG-IFN, pegylated interferon; RIB, ribavirin; TRV, telaprevir; SMV, simeprevir; RAV; resistance-associated variant.
Data are the number or median (range); ^aMann Whitney U test, ^bFisher’s exact test.

Quick links

Search